Combination of abiraterone and cabazitaxel in metastatic castration-resistant prostate cancer

Share :
Published: 27 Feb 2015
Views: 2749
Rating:
Save
Dr Joaquin Mateo - Institute of Cancer Research, London, UK

Dr Joaquin Mateo speaks to ecancertv at ASCO GU 2015 following results from the Phase II trial using abiraterone and cabazitaxel combination in metastatic castration-resistant prostate cancer where it's found to be well tolerated and demonstrated antitumor activity in the post-docetaxel, post-abiraterone setting.